SCHEDULE 13G: Ridgeback Capital Reduces Stake in iTeos Therapeutics to 3.8%

Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC have collectively reduced their beneficial ownership in iTeos Therapeutics, Inc. to 3.8% of outstanding common stock as of June 4, 2025.

Summary

• The filing identifies Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC as the Reporting Persons.
• The issuer is iTeos Therapeutics, Inc., with its common stock (CUSIP 46565G104) being the subject security.
• As of June 4, 2025, the Reporting Persons beneficially owned an aggregate of 1,442,959 shares of iTeos Therapeutics common stock.
• This ownership represents 3.8% of the outstanding common stock of iTeos Therapeutics, Inc.
• The Reporting Persons hold shared voting power and shared dispositive power over all 1,442,959 beneficially owned shares.
• This stake is a reduction from the 1,942,959 shares, or 5.1% of outstanding shares, beneficially owned by the Reporting Persons as of May 28, 2025.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 4

Explanation: The document reports a reduction in a significant institutional stake, which is generally viewed negatively by the market as it suggests a decrease in confidence or a portfolio reallocation by a major investor. While the filing itself is factual and neutral, the underlying action of reducing ownership is typically interpreted as a bearish signal.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a change in institutional ownership for iTeos Therapeutics, a biotechnology company. Such changes are common in the biotech sector, where investment firms frequently adjust positions based on clinical trial progress, regulatory milestones, or broader market sentiment. A reduction in stake by an investment firm like Ridgeback Capital could be a routine portfolio adjustment or a signal of a revised outlook on the company's prospects, though the filing itself does not provide the rationale.

Stakeholder Impact

• Shareholders may perceive the reduction in institutional ownership as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Keywords

iTeos Therapeutics, Ridgeback Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, Equity Stake, Biotechnology, Pharmaceuticals